4/A: CFO Stephen Feider Acquires Beta Bionics Stock Options

Beta Bionics' CFO, Stephen Feider, acquired 110,342 employee stock options with an exercise price of $12.63, vesting over 36 months.

Summary

• Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), acquired 110,342 employee stock options.
• The options have an exercise price of $12.63 per share.
• The earliest transaction date for this acquisition was February 27, 2026.
• The options will vest in 36 equal monthly installments, starting from March 1, 2026.
• The expiration date for these options is February 26, 2036.
• Following this transaction, Mr. Feider beneficially owns 110,342 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as insider option acquisitions can indicate management's confidence in future stock appreciation, though it's a routine compensation event.

Positives

• Acquisition of stock options by a key executive (CFO) can signal confidence in the company's future performance.
• The options have a long expiration date (February 26, 2036), providing a significant window for potential value realization.

Risks

• The value of the stock options is dependent on the future performance of Beta Bionics' common stock. If the stock price does not exceed the exercise price of $12.63, the options may expire worthless.
• The vesting schedule ties the executive's compensation to long-term company performance, but also means the full benefit is not immediately realized.

Future Outlook

The vesting schedule of the options over 36 months from March 1, 2026, indicates a long-term incentive structure for the CFO, aligning his interests with the company's sustained future growth and stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to key executives like the CFO is a standard practice in the biotechnology and medical device industry (where Beta Bionics operates, given its name) to incentivize long-term performance and retain talent. This aligns executive compensation with shareholder value creation.

Comparison to Industry Standards

• The exercise price of $12.63 is specific to BBNX's valuation at the time of grant.
• A 36-month vesting schedule is common for executive equity awards, comparable to practices at companies like Dexcom (DXCM) or Insulet (PODD), which also operate in the diabetes management technology space.
• The total number of options granted (110,342) would need to be assessed against Mr. Feider's overall compensation package and the company's total outstanding shares to determine its relative significance, similar to how grants are evaluated at peer companies.

Related Party Transactions

• The transaction is an employee stock option grant to an officer, which is a common form of related-party compensation.

Stakeholder Impact

• Shareholders: The acquisition of options by the CFO aligns his interests with shareholders, as the options gain value if the stock price increases. Potential future dilution if options are exercised.
• Employees: This is a form of executive compensation, which can set a precedent for other employee incentive programs.

Next Steps

• The options will vest in 36 equal monthly installments starting March 1, 2026.
• Mr. Feider may exercise these options at any time after they vest and before the expiration date of February 26, 2036.

Key Dates

Keywords

Beta Bionics, BBNX, Stephen Feider, CFO, Stock Options, Insider Trading, SEC Form 4, Equity Compensation, Beneficial Ownership